title: Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis.
authors.forename: K
authors.initials: K
authors.lastname: Visser
authors.forename: K N
authors.initials: KN
authors.lastname: Verpoort
authors.forename: H
authors.initials: H
authors.lastname: van Dongen
authors.forename: S M
authors.initials: SM
authors.lastname: van der Kooij
authors.forename: C F
authors.initials: CF
authors.lastname: Allaart
authors.forename: R E M
authors.initials: RE
authors.lastname: Toes
authors.forename: T W J
authors.initials: TW
authors.lastname: Huizinga
authors.forename: A H M
authors.initials: AH
authors.lastname: van der Helm-van Mil
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood*; D015331:Cohort Studies; D006801:Humans; D016015:Logistic Models; D008727:Methotrexate / Q000009:adverse effects* / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000276:immunology*; D011379:Prognosis
chemical_list: D018501:Antirheumatic Agents; D001323:Autoantibodies; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide; D008727:Methotrexate